Dev Prasad
Stock Analyst at Lucid Capital
(4.74)
# 637
Out of 4,534 analysts
15
Total ratings
78.6%
Success rate
96.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dev Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QNRX Quoin Pharmaceuticals | Initiated Coverage: Buy | $30 | $4.21 | +612.59% | 1 | May 4, 2026 | |
| ABOS Acumen Pharmaceuticals | Initiated Coverage: Buy | $6 | $2.21 | +171.49% | 1 | Dec 17, 2025 | |
| PVLA Palvella Therapeutics | Maintained: Buy | $49 → $212 | $124.15 | +70.76% | 2 | Dec 15, 2025 | |
| IFRX InflaRx | Maintained: Buy | $24 | $1.82 | +1,218.68% | 1 | Nov 10, 2025 | |
| VRCA Verrica Pharmaceuticals | Initiated Coverage: Buy | $19 | $5.49 | +246.08% | 1 | Nov 5, 2025 | |
| TSX: MDNA Medicenna Therapeutics Corp. | Initiated Coverage: Buy | $4.00 | $0.35 | +1,042.86% | 1 | Oct 14, 2025 | |
| ATYR aTyr Pharma | Downgraded: Hold | $1 | $0.4864 | +105.59% | 1 | Sep 15, 2025 | |
| CUE Cue Biopharma | Initiated Coverage: Buy | $4 | $30.95 | -87.08% | 1 | Aug 25, 2025 | |
| IRD Opus Genetics | Initiated Coverage: Buy | $5 | $3.05 | n/a | 1 | Jun 17, 2025 | |
| EDSA Edesa Biotech | Initiated Coverage: Buy | $9 | $5.82 | n/a | 1 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $36 | $5.28 | n/a | 1 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $6 | $1.37 | n/a | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $24 | $18.21 | n/a | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $0.7045 | n/a | 1 | Dec 17, 2024 |
Quoin Pharmaceuticals
May 4, 2026
Initiated Coverage: Buy
Price Target: $30
Current: $4.21
Upside: +612.59%
Acumen Pharmaceuticals
Dec 17, 2025
Initiated Coverage: Buy
Price Target: $6
Current: $2.21
Upside: +171.49%
Palvella Therapeutics
Dec 15, 2025
Maintained: Buy
Price Target: $49 → $212
Current: $124.15
Upside: +70.76%
InflaRx
Nov 10, 2025
Maintained: Buy
Price Target: $24
Current: $1.82
Upside: +1,218.68%
Verrica Pharmaceuticals
Nov 5, 2025
Initiated Coverage: Buy
Price Target: $19
Current: $5.49
Upside: +246.08%
Medicenna Therapeutics Corp.
Oct 14, 2025
Initiated Coverage: Buy
Price Target: $4.00
Current: $0.35
Upside: +1,042.86%
aTyr Pharma
Sep 15, 2025
Downgraded: Hold
Price Target: $1
Current: $0.4864
Upside: +105.59%
Cue Biopharma
Aug 25, 2025
Initiated Coverage: Buy
Price Target: $4
Current: $30.95
Upside: -87.08%
Opus Genetics
Jun 17, 2025
Initiated Coverage: Buy
Price Target: $5
Current: $3.05
Upside: n/a
Edesa Biotech
May 23, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $5.82
Upside: n/a
May 1, 2025
Initiated Coverage: Buy
Price Target: $36
Current: $5.28
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $6
Current: $1.37
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $24
Current: $18.21
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $13
Current: $0.7045
Upside: n/a